title: Differential effect of intestinal neuropeptides on invasion and migration of colon carcinoma cells in vitro.
abstract: We investigated the effect of neuropeptides, which are vasoactive intestinal polypeptide (VIP), substance P, (SP), neuropeptide Y (NPY), neurokinin A (NKA), somatostatin (SOM), calcitonin gene-related peptide (CGRP), and leucine-enkephalin (L-ENK), on the invasion of murine Colon 26-L5 adenocarcinoma cells through a reconstituted basement membrane (Matrigel) using a Transwell cell culture chamber assay. VIP, SP, NPY, and L-ENK reduced invasive potential of tumor cells in a concentration-dependent manner, whereas SOM, CGRP, and NKA had no effect. Especially, VIP showed the most effective in inhibiting tumor invasion, and achieved 50% reduction at 10(-6) M. A similar effect by VIP was also observed in cell migration to fibronectin. VIP had no effect on the growth of tumor cells at the concentrations ranging from 10(-10) to 10(-6) M. The suppressed ability of the tumor cell motility by VIP (10(-6) M) was practically recovered by co-treatment with 2',5'-dideoxyadenosine, an adenylate cyclase inhibitor. These results indicate that VIP, among the neuropeptides used, could inhibit Matrigel invasion of Colon 26-L5 carcinoma cells through partial suppression of their motility, and the reduction was associated with an intracellular cAMP-mediated pathway.
authors.affiliation: Department of Pathogenic Biochemistry, Research Institute for Wakan-yaku, Toyama Medical and Pharmaceutical University, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ogasawara
authors.forename: J
authors.initials: J
authors.lastname: Murata
authors.forename: K
authors.initials: K
authors.lastname: Ayukawa
authors.forename: I
authors.initials: I
authors.lastname: Saimi
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000818:Animals; D001672:Biocompatible Materials; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D005576:Colforsin / Q000494:pharmacology; D003094:Collagen / Q000502:physiology; D003110:Colonic Neoplasms / Q000473:pathology*; D016048:Dideoxyadenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004745:Enkephalins / Q000494:pharmacology; D007797:Laminin / Q000502:physiology; D007930:Leucine / Q000494:pharmacology; D051379:Mice; D009361:Neoplasm Invasiveness / Q000473:pathology*; D015288:Neurokinin A / Q000494:pharmacology; D009478:Neuropeptide Y / Q000494:pharmacology; D009479:Neuropeptides / Q000494:pharmacology*; D011509:Proteoglycans / Q000502:physiology; D013004:Somatostatin / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
chemical_list: D001672:Biocompatible Materials; D004338:Drug Combinations; D004745:Enkephalins; D007797:Laminin; D009478:Neuropeptide Y; D009479:Neuropeptides; D011509:Proteoglycans; C059485:matrigel; D005576:Colforsin; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D016048:Dideoxyadenosine; D013004:Somatostatin; D015288:Neurokinin A; D003094:Collagen; C021008:2',5'-dideoxyadenosine; D007930:Leucine; D015740:Calcitonin Gene-Related Peptide